MX2022003037A - Compuestos antibacterianos. - Google Patents
Compuestos antibacterianos.Info
- Publication number
- MX2022003037A MX2022003037A MX2022003037A MX2022003037A MX2022003037A MX 2022003037 A MX2022003037 A MX 2022003037A MX 2022003037 A MX2022003037 A MX 2022003037A MX 2022003037 A MX2022003037 A MX 2022003037A MX 2022003037 A MX2022003037 A MX 2022003037A
- Authority
- MX
- Mexico
- Prior art keywords
- antibacterial compounds
- compounds
- tuberculosis
- medicaments
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19197183 | 2019-09-13 | ||
| PCT/EP2020/075458 WO2021048342A1 (en) | 2019-09-13 | 2020-09-11 | Antibacterial compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022003037A true MX2022003037A (es) | 2022-04-07 |
Family
ID=67956507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003037A MX2022003037A (es) | 2019-09-13 | 2020-09-11 | Compuestos antibacterianos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220340564A1 (enExample) |
| EP (1) | EP4028399B1 (enExample) |
| JP (1) | JP7680433B2 (enExample) |
| KR (1) | KR102955654B1 (enExample) |
| CN (1) | CN114423758B (enExample) |
| AU (1) | AU2020346370B2 (enExample) |
| BR (1) | BR112022003799A2 (enExample) |
| CA (1) | CA3149868A1 (enExample) |
| ES (1) | ES2978573T3 (enExample) |
| MX (1) | MX2022003037A (enExample) |
| WO (1) | WO2021048342A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20181352A1 (es) | 2015-09-17 | 2018-08-22 | Marvin J Miller | Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias |
| WO2022194803A1 (en) * | 2021-03-16 | 2022-09-22 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| CA3234515A1 (en) | 2021-10-28 | 2023-05-04 | Jose Manuel Bartolome-Nebreda | Imidazopyridine amides and related compounds for use in the treatment of bacterial infections |
| EP4296674A1 (en) | 2022-06-20 | 2023-12-27 | Université Toulouse III - Paul Sabatier | Innovative molecules decreasing virulence of mycobacterium for the treatment of tuberculosis |
| WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2024223859A1 (en) | 2023-04-26 | 2024-10-31 | Janssen Pharmaceutica Nv | Antibacterial compounds |
| JP2026525955A (ja) | 2023-07-18 | 2026-08-04 | ヤンセン ファーマシューティカ エヌ．ベー． | ベダキリン、プレトマニド又はデラマニド、及びシトクロムｂｃ１阻害剤を含む、少なくとも三種の抗生物質の組み合わせ製品、並びにマイコバクテリア感染症の治療におけるそれらの使用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1527050T1 (sl) | 2002-07-25 | 2010-08-31 | Janssen Pharmaceutica Nv | Kinolinski derivati in njihova uporaba kot mikobakterijski inhibitorji |
| RU2576662C2 (ru) | 2010-03-18 | 2016-03-10 | Энститю Пастер Корея | Противоинфекционные соединения |
| US8569283B2 (en) | 2011-09-01 | 2013-10-29 | Valentina Molteni | Compounds and compositions as c-Kit kinase inhibitors |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| JP6483610B2 (ja) * | 2012-07-18 | 2019-03-13 | ユニバーシティ オブ ノートルダム デュ ラック | ５，５−ヘテロ芳香族抗感染症化合物 |
| WO2015014993A2 (en) | 2013-08-02 | 2015-02-05 | Institut Pasteur Korea | Anti-infective compounds |
| CN105524058B (zh) * | 2014-10-21 | 2018-03-27 | 广州艾格生物科技有限公司 | 吡唑并[1,5‑a]吡啶类化合物及其应用 |
| MD3316969T2 (ro) | 2015-07-02 | 2022-07-31 | Janssen Sciences Ireland Unlimited Co | Compuși antibacterieni |
| PE20181352A1 (es) | 2015-09-17 | 2018-08-22 | Marvin J Miller | Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias |
| MA45377A (fr) | 2016-06-16 | 2019-04-24 | Janssen Sciences Ireland Unlimited Co | Composés hétérocycliques en tant qu'agents antibacteriens |
| EP3472152A1 (en) | 2016-06-16 | 2019-04-24 | Janssen Sciences Ireland Unlimited Company | Heterocyclic compounds as antibacte rials |
| WO2018084809A1 (en) * | 2016-11-02 | 2018-05-11 | Nanyang Technological University | Methods for the treatment or prevention of mycobacterial infections |
-
2020
- 2020-09-11 CN CN202080064727.XA patent/CN114423758B/zh active Active
- 2020-09-11 WO PCT/EP2020/075458 patent/WO2021048342A1/en not_active Ceased
- 2020-09-11 AU AU2020346370A patent/AU2020346370B2/en active Active
- 2020-09-11 JP JP2022516117A patent/JP7680433B2/ja active Active
- 2020-09-11 ES ES20776062T patent/ES2978573T3/es active Active
- 2020-09-11 KR KR1020227011475A patent/KR102955654B1/ko active Active
- 2020-09-11 BR BR112022003799A patent/BR112022003799A2/pt unknown
- 2020-09-11 EP EP20776062.0A patent/EP4028399B1/en active Active
- 2020-09-11 MX MX2022003037A patent/MX2022003037A/es unknown
- 2020-09-11 US US17/639,963 patent/US20220340564A1/en active Pending
- 2020-09-11 CA CA3149868A patent/CA3149868A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2978573T3 (es) | 2024-09-16 |
| KR102955654B1 (ko) | 2026-04-21 |
| KR20220062564A (ko) | 2022-05-17 |
| JP2022548247A (ja) | 2022-11-17 |
| CN114423758A (zh) | 2022-04-29 |
| CN114423758B (zh) | 2025-05-27 |
| CA3149868A1 (en) | 2021-03-18 |
| US20220340564A1 (en) | 2022-10-27 |
| AU2020346370A1 (en) | 2022-05-05 |
| JP7680433B2 (ja) | 2025-05-20 |
| BR112022003799A2 (pt) | 2022-05-24 |
| AU2020346370B2 (en) | 2026-02-12 |
| EP4028399B1 (en) | 2024-02-14 |
| EP4028399C0 (en) | 2024-02-14 |
| EP4028399A1 (en) | 2022-07-20 |
| WO2021048342A1 (en) | 2021-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017013408A2 (es) | Compuestos bicíclicos heterocíclicos como agentes antituberculares. | |
| CL2020003007A1 (es) | Lactamas biciclicas y metodos de uso de las mismas (divisional solicitud no. 3486-2017) | |
| ECSP20021913A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso | |
| CL2021001042A1 (es) | Nuevos compuestos antihelmínticos | |
| MX2022012313A (es) | Oxisteroles y metodos de uso de los mismos. | |
| UY37201A (es) | Nuevos derivados de pirazolopirimidina | |
| UY37435A (es) | Pirrolidinas sustituidas y métodos para usarlas | |
| CR20170575A (es) | Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los continen. | |
| SV2016005257A (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| NI201800076A (es) | Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| GT201600091A (es) | Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos | |
| CL2019003398A1 (es) | Inhibidores pirazólicos de magl. | |
| CL2018000786A1 (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| MX2016014547A (es) | Compuestos para tratar atrofia muscular espinal. | |
| MX2012003101A (es) | Derivados de pirimidina como inhibidores de la proteina tirosina quinasa 2. | |
| CU20200008A7 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen | |
| CL2019003213A1 (es) | Compuestos plaguicidas bicíclicos. | |
| CO2017007325A2 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
| UY35295A (es) | ?Compuestos microbicidas novedosos, métodos para su uso y composiciones?. | |
| MX2018008772A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
| UY37250A (es) | Derivados macrocíclicos de indol | |
| CL2020001062A1 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos. | |
| BR112022003799A2 (pt) | Compostos antibacterianos | |
| CO2018011231A2 (es) | Derivados de [1,2,3]triazolo[4,5-d]pirimidina con afinidad por los receptores canabinoides tipo-2 | |
| MX2020001808A (es) | Nuevos compuestos. |